Journal
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
Volume 11, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40164-022-00353-3
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81890994]
- National Key R&D Program of China [2019YFA0905902]
- Guangdong Basic and Applied Basic Research Foundation [2019A1515010299]
- Guangzhou Science and Technology Plan Project [202102020727]
- Innovative Research Team of High-level Local Universities in Shanghai
- Dean'fund of Zhujiang Hospital, Southern Medical University [yzjj2019qn05]
Ask authors/readers for more resources
Neoantigens derived from non-synonymous somatic mutations are considered ideal targets for T cell receptor (TCR)-based immunotherapy. High-avidity TCRs specific for neoantigens expressed on AML cells have been identified and show great potential as safe and effective therapies. TCR-based immunotherapies also demonstrate encouraging anti-leukemic effects in early-phase clinical trials for AML.
Neoantigens derived from non-synonymous somatic mutations are restricted to malignant cells and are thus considered ideal targets for T cell receptor (TCR)-based immunotherapy. Adoptive transfer of T cells bearing neoantigen-specific TCRs exhibits the ability to preferentially target tumor cells while remaining harmless to normal cells. High-avidity TCRs specific for neoantigens expressed on AML cells have been identified in vitro and verified using xenograft mouse models. Preclinical studies of these neoantigen-specific TCR-T cells are underway and offer great promise as safe and effective therapies. Additionally, TCR-based immunotherapies targeting tumor-associated antigens are used in early-phase clinical trials for the treatment of AML and show encouraging anti-leukemic effects. These clinical experiences support the application of TCR-T cells that are specifically designed to recognize neoantigens. In this review, we will provide a detailed profile of verified neoantigens in AML, describe the strategies to identify neoantigen-specific TCRs, and discuss the potential of neoantigen-specific T-cell-based immunotherapy in AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available